• E-mail :[email]
  • Phone : +33 2 44 68 85 43
  • Location : Angers, France
Last update 2011-08-22 17:24:18.861


Course and current status

2005- Research Associate Inserm (Neuro-Oncology and Nanomedicines), Inserm U646 - Angers, France

2004 HDR "Habilitation à Diriger des Recherches" - University of Angers - Angers, France

2002-2004 Research Associate (Neuro-Oncology and Nanomedicines), Inserm ERIT-M 0104 - Angers, France

1998-2001 Research Associate (Developmental Neurobiology), University of Cambridge, Wellcome-CRC Institute & Brain Repair Center - Cambridge, UK

1997 PhD in Neurosciences, University of Pierre & Marie Curie (UPMC) - Paris, France

1994-1997 PhD student (Neuro-immunology), Inserm U298 - Angers, France

Scientific summary

Topic: Nanomedicine and Cellular Delivery of therapeutic molecules in neuro-oncology

Special Interests:

  • Targeting cancer stem cells in glioblastoma
  • Subcellular routing of anticancer agents
  • miRNA, hypoxia and radiation résistance

Parallel to the identification of relevant targets, the major problem imposed by cancer remains the resistance to treatment. Glioblastoma, primary tumor from the central nervous system (CNS) whose treatment is only palliative, represented a dramatic illustration of this reality. This failure is generally due to the infiltrating properties of glioblastoma cells, to the overexpression of repair and survival proteins, but also a non-optimal treatment administration. The recent identification of cancer-initiating cells in glioblastomas and the existence of cancer stem cells (CSC) supported the presumption that limit of conventional antitumor strategies can still be attributed to a problem of target cells. It become, therefore, urgent to design a technological base that can generate more efficacies while allowing an optimum of specificity and safety. The emergence of nanomedicines offers here interesting perspectives. Due to their submicron size and physicochemical properties modular nanostructures may interact in a unique fashion with biological systems. They can offer new opportunities for drug delivery for example by helping to cross biological barriers or protecting a premature elimination. By developing models of glioma in animals (syngeneic rats and mice models or xenogeneic human to mouse models), our work is to interpret the fundamental mechanisms that underlie the development of glioblastoma and to develop relevant chemo or radiosentizing nanomedicines in order to obtain curative values. A particular attention is paid to the selection of subpopulations of cancer-initiating cell, the role of miRNAs and the intrincellular behavior of the developed drug nanocarriers. The originality of this work is the development of intelligent minimally-invasive tools combined with the evaluation of their biological properties in well defined physiological and pathophysiological situations.

Image d’exemple